TuHURA Biosciences Files 8-K on Operations

Ticker: HURA · Form: 8-K · Filed: Apr 1, 2025 · CIK: 1498382

Sentiment: neutral

Topics: 8-K, financial-condition, operations

TL;DR

TuHURA Biosciences (fka Kintara) filed an 8-K on April 1st detailing its financial condition.

AI Summary

TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on April 1, 2025, reporting on its results of operations and financial condition. The filing indicates the company is incorporated in Nevada and its fiscal year ends on December 31st. TuHURA Biosciences is involved in the Pharmaceutical Preparations industry.

Why It Matters

This 8-K filing provides an update on TuHURA Biosciences' operational and financial status, which is crucial for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting operational and financial information, not indicating any immediate significant risks or events.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for TuHURA Biosciences, Inc.?

The primary purpose is to report on the company's Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.

What was TuHURA Biosciences, Inc. formerly known as?

TuHURA Biosciences, Inc. was formerly known as Kintara Therapeutics, Inc., DelMar Pharmaceuticals, Inc., and Berry Only Inc.

In which U.S. state is TuHURA Biosciences, Inc. incorporated?

TuHURA Biosciences, Inc. is incorporated in Nevada.

What is the Standard Industrial Classification (SIC) code for TuHURA Biosciences, Inc.?

The SIC code for TuHURA Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

On what date was this 8-K filing made?

This 8-K filing was made on April 1, 2025.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 1, 2025 regarding TuHURA Biosciences, Inc./NV (HURA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing